Autoimmune polyglandular syndrome type 1 in a 12-year-old Ugandan girl by Kibirige, D & Kambugu, F
Case Study: Autoimmune polyglandular syndrome type 1 in a 12-year-old Ugandan girl
65 2013 Volume 18 No 1JEMDSA
Introduction
Autoimmune polyendocrinopathy-candidiasis-ecto-
dermal dystrophy syndrome (APS-1), is an extremely 
rare and frequently debilitating disorder of childhood. 
A clinical diagnosis of APS-1 classically requires the 
presence of two of the three cardinal components: 
chronic mucocutaneous candidiasis, autoimmune 
hypoparathyroidism and autoimmune adrenal failure.1 
Typically, the first manifestation is mucocutaneous 
candidiasis, which develops in infancy or early 
childhood. This is followed by the development of 
hypoparathyroidism, which may be asymptomatic 
or which typically presents with tetany and seizures. 
Adrenal insufficiency often develops later. Other 
conditions which are associated with APS-1 include 
autoimmune thyroid disease, type 1 diabetes, hypo-
gonadism, alopecia, vitiligo, autoimmune hepatitis, 
pernicious anaemia and chronic gastritis.2
There are no documented case reports of APS-1 
among African patients. Most of the described case 
reports are from Europe3-7 and the Middle East.8
Case study
A 12-year-old female patient was referred to the 
dermatology unit of Mulago National Referral and 
Teaching Hospital, Uganda. She had a six-year history 
of a generalised, intensely itchy skin rash on the limbs, 
trunk and face. The rash was initially responsive to 
topical steroid therapy, but was later refractory. The 
patient had a three-year history of progressive wart-like 
growths on the face and scalp. She also presented with 
a three-month history of nail deformities and oral sores. 
Her history was not suggestive of any autoimmune 
condition. There was no familial history of autoimmune 
conditions or of a similar condition among her siblings.
A physical examination revealed extensive facial and 
scalp growths with alopecia (Figure 1) and widespread 
oral thrush and angular cheilitis. There were generalised 
scaly skin lesions on the hands and legs (Figure 2), 
and markedly thickened, pitted nails with a distorted 
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Abstract
Autoimmune polyglandular syndrome type 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome, is a very rare disorder of childhood. It is mainly characterised by the presence of 
at least two of the following: chronic mucocutaneous candidiasis, chronic hypoparathyroidism and autoimmune 
Addison’s disease. We report on the case of a 12-year-old Ugandan female patient who presented with features 
that were most consistent with APS-1 (chronic mucocutaneous candidiasis and hypoparathyroidism). Significant 
clinical improvement was noted following oral antifungal therapy. 
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Figure 1: Extensive facial and scalp growths with alopecia 
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appearance (Figure 3). Chovstek’s and Trousseau’s 
signs were negative. Her height and body mass index 
were normal for her age (height of 1.3 m, weight of 
31 kg and body mass index of 18.3 kg/m2). She had 
normal secondary sexual characteristics for her age 
(Tanner stage II).
The haematological evaluation that was carried 
out showed a mild hypoalbuminaemia of 32.7 g/dl 
(normal range 35-50). The complete blood count and 
renal and liver function tests were normal. Human 
immunodeficiency virus serology was negative. She 
had a mild corrected hypocalcaemia of 8.4 mg/
dl (normal range 9-10.6 mg/dl), and the parathyroid 
hormone levels were reduced (6 pg/ml, normal range 
15-65 pg/ml). Serum phosphorus, magnesium and 
vitamin D levels were not ascertained.
An endocrine screen was performed to rule out any 
co-existing autoimmune conditions. Thyroid function 
tests, fasting blood glucose, follicle-stimulating 
hormone, oestradiol, luteinising hormone and cortisol 
levels at 08h00 were all normal. Skin scrapings for 
fungal culture were not taken. Genetic testing for the 
different mutations of the autoimmune regulator (AIRE) 
gene was also not carried out because it cannot be 
performed in Uganda.
A diagnosis of APS-1 was made on the basis of the 
presence of chronic mucocutaneous candidiasis and 
hypoparathyroidism. The patient was started on oral 
vitamin D and calcium supplementation to treat the 
hypoparathyroidism, as well as on daily oral fluconazole. 
Significant clinical improvement was noticed within 
three weeks, with total resolution of the facial and 
scalp growths (Figures 4 a and b). To date, her clinical 
Figure 2: Generalised scaly skin lesions on the hands and legs
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follow-up and endocrine screening for associated 
autoimmune conditions has been uneventful.
Discussion
In this case report, we report on the case of a 
young African patient with typical features of APS-1 
(mucocutaneous candidiasis, hypoparathyroidism and 
alopecia areata). These cardinal clinical features are 
similar to those that have been reported elsewhere in 
patients with APS-1.
To our knowledge, this is the first documented case 
report of APS-1 from Africa. APS-1 has been noted 
to occur more frequently among homogeneous 
populations, such as those in Finland,3 northern Italy,4 
Norway5 and Sardinia,6 as well as among Iranian Jews.8 
APS-1 is an extremely rare condition that is 
characterised by multiple, organ-specific autoimmune 
and mucocutaneous manifestations. It is an autosomal-
recessive condition and a monogenic disorder linked 
to a defect of the AIRE gene located on chromosome 
21q22.3.9 
The AIRE protein is thought to play a role in the thymic 
process of induction of self-tolerance, its maintenance 
and the regulation of transcription.10 
Early immunogenetic testing for the different mutations 
of the AIRE gene and human leukocyte antigen (HLA) 
typing are essential for identification of patients at risk. 
This is because APS-1 occurs sporadically or in siblings.11 
HLA-A28 has been demonstrated to occur more 
frequently in patients with APS-1 than in normal controls. 
Generally, HLA-A3 is mostly observed in patients with 
APS-1 and ovarian failure.12 However, these tests are 
not readily available in most resource-limited settings.
Chronic mucocutaneous candidiasis is a frequent 
cutaneous manifestation in APS-1. Usually, it develops 
because of a selective immunological deficiency 
which involves the T-cell lineage that predisposes the 
patient to Candida albicans. Patients with APS-1 still 
possess a normal B-cell response which prevents the 
development of systemic candidiasis.13
Endocrine evaluation is of paramount importance in 
patients with APS-1. This is because a wide spectrum 
of endocrine and non-endocrine conditions occur at 
varying frequencies.11 These include hypergonadotropic 
hypogonadism, autoimmune thyroid diseases, type 1 
diabetes mellitus, pernicious anaemia, celiac disease, 
autoimmune hepatitis, vitiligo and alopecia areata.7 In 
our case, on evaluation, the patient did not have any 
additional endocrine condition.
Patients with APS-1 should be followed-up on a 
regular basis because the majority of the above 
conditions develop later in the course of the disease.11 
Functional screening, by measuring organ-specific 
autoantibodies, aids in confirming the diagnosis of 
autoimmune conditions, and also in identifying patients 
who are at risk of developing other endocrinopathies.1
Conclusion
The common occurrence of chronic mucocutaneous 
candidiasis among patients with APS-1 signifies its 
relevance in the diagnosis. Since the majority of other 
autoimmune disease components develop later in 
life, long-term follow-up and endocrine evaluation are 
integral aspects in the management of patients with 
APS-1.  
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